Comparative Pharmacology
Head-to-head clinical analysis: GLUCOVANCE versus KAZANO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOVANCE versus KAZANO.
GLUCOVANCE vs KAZANO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLUCOVANCE (glyburide/metformin) combines a sulfonylurea (glyburide) that stimulates insulin secretion from pancreatic beta cells by inhibiting ATP-sensitive potassium channels, and a biguanide (metformin) that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Kazano is a combination of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin, a biguanide. Alogliptin inhibits DPP-4, increasing incretin levels (GLP-1 and GIP), which enhances glucose-dependent insulin secretion and suppresses glucagon release. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Initial: 1.25 mg glyburide/250 mg metformin once daily. Titrate gradually up to 10 mg glyburide/2000 mg metformin daily based on glycemic response. Administered orally with meals.
Oral: 1 tablet (alogliptin 12.5 mg / metformin 500 mg) twice daily with meals. Maximum dose: alogliptin 25 mg / metformin 2000 mg per day.
None Documented
None Documented
Metformin: plasma terminal half-life ~6.2 h (renal impairment prolongs); Glyburide: half-life ~10 h (range 7–20 h, prolonged in hepatic impairment).
Metformin: terminal elimination half-life ~6.2 hours (plasma), prolonged to ~17.6 hours in renal impairment. Alogliptin: terminal elimination half-life ~21 hours, allowing once-daily dosing.
Renal: ~90% (metformin, unchanged, via tubular secretion); Fecal: ~5% (glyburide metabolites); Biliary: minor (<5% for both).
Metformin: ~90% unchanged via renal (glomerular filtration and tubular secretion). Alogliptin: ~76% unchanged renal, ~13% fecal. Approximately 89% of total clearance is renal for alogliptin.
Category C
Category C
Antidiabetic Combination (Sulfonylurea + Biguanide)
Antidiabetic Combination (DPP-4 Inhibitor + Biguanide)